Patient with human immunodeficiency virus HIV / AIDS, non- Hodking lymphoma and atypical mycobacteriosis
Abstract
In HIV-positive patients, infections caused by atypical mycobacteria are particularly serious because of the rapid onset of immunosuppression. Therefore, this reasearch aims at illustrating the diagnostic complexity of an HIV-positive case, adherent to antirretroviral treatment, who developed non-Hodgkin lymphoma, resulting in significant immunosupression that reactivated atypical mycobacteriosis despite the patient having adequate viral loads and CD4 T lymphocyte counts. Diagnosis became a challenge despite medical efforts, ultimately leading to a fatal outcome.
Downloads
References
1.Organización Mundial de la Salud. Estrategias mundiales del sector de la salud contra el VIH, las hepatitis víricas y las infecciones de transmisión sexual para el periodo 2022-2030. Ginebra: Organización Mundial de la Salud; 2025 [citado 29/01/2026]: 136. Disponible en: https://iris.who.int/server/api/core/bitstreams/efaf3bab-4386-4104-8e69-1a8b8ee052cc/content
2. Rozas CF, Cifuentes MM, Flores K, Salinas P D, Troncoso A T, Saldías P F. Caracterización clínica y microbiológica de pacientes no VIH con micobacteriosis atípica pulmonar: experiencia de un centro público. Rev Chil Enferm Respir. 2024[citado 29/01/2026];40(2):118-28. Disponible en: https://revchilenfermrespir.cl/index.php/RChER/article/view/1207/1986
3. Esteban J, Navas E. Tratamiento de las infecciones producidas por micobacterias no tuberculosas. Enferm Infecc Microbiol Clin. 2018[citado 29/01/2026];36(9):586-92. Disponible en: https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-pdf-S0213005X17303026
4. Vivas Arteaga JS. Linfoma difuso de células B grandes (LDCBG): epidemiología, clasificación, pronóstico y tratamiento. NPunto. 2025[citado 29/01/2026];8(92):3-4. Disponible en: https://www.npunto.es/revista/92/linfoma-difuso-de-celulas-b-grandes-ldcbg-epidemiologia-clasificacion-pronostico-y-tratamiento
5. Hübel K. The changing landscape of lymphoma associated with HIV infection. Current Oncology Reports. 2020[citado 19/10/2025];22(11):111. Disponible en:https://pmc.ncbi.nlm.nih.gov/articles/PMC8302507/pdf/11912_2020_Article_973.pdf
6. Lange CH, Bothamley G, Günther G, Guglielmetti L, Kontsevaya I , Kuksa L, et al. A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists. Pathogens and Immunity. 2024[citado 29/10/2025];10(2):1-45. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC11888605/pdf/pai-10-001.pdf
7. Nguyen MVH, Haas MK, Kasperbauer SH, Calado Nogueira de Moura V, Eddy JJ, Mitchell JD, et al. Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects. Clinical Infectious Diseases. 2024[citado 20/11/2025];79(15): e27. Disponible en: https://www.cofybcf.org.ar/src/img_up/13112024.0.pdf
8. Chalmers JD, Aksamit T, Carvalho ACC, Rendon A, Franco I. Non-tuberculous mycobacterial pulmonary infections. Pulmonology Journal. 2018[citado 29/12/2025];24(2):120-31. Disponible en: https://journalpulmonology.org/en-pdf-S2531043718300199
9. Lipman M, Kunst H, Loebingere MR, Milburng HJ, King M. Non tuberculous mycobacteria pulmonary disease: patients and clinicians working together to improve the evidence base for care. International Journal of Infectious Diseases. 2021[citado 20/01/2026];5266:5 Disponible en: https://discovery.ucl.ac.uk/id/eprint/10125716/9/Lipman_Non%20tuberculous%20mycobacteria%20pulmonary%20disease%20patients%20and%20clinicians%20working%20together%20to%20improve%20the%20evidence%20base%20for%20care_AOP.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Lázaro Rafael Rodríguez Cabrera, Milena Duque Vizcaino, Ailyn Machado Sosa
This work is licensed under a Creative Commons Attribution 4.0 International License.
All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.
![Secimed](/templates/images/secimed.png"){kind=small}
